Volume 2.46 | Dec 9

Mammary Cell News 2.46 December 9, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Inositol Polyphosphate 4-Phosphatase II Regulates PI3K/Akt Signaling and Is Lost in Human Basal-Like Breast Cancers  ShareThis
Researchers report here that inositol polyphosphate 4-phosphatase-II is expressed in nonproliferative estrogen receptor (ER)-positive cells in the normal breast, and in ER-positive, but not negative, breast cancer cell lines. [Proc Natl Acad Sci USA]

Watch Procedure Now  
Learn to Enumerate Mammospheres and Tumorspheres
Cultured in MammoCult®
by STEMCELL Technologies
 
 
WATCH PROCEDURE NOW STEMCELL Technologies Inc
 



SPECIAL FEATURE

George W. Sledge Jr., M.D., Honored for International Contributions to Breast Cancer Research
George W. Sledge Jr., M.D., a nationally recognized pioneer in the development of novel therapies for breast cancer, will receive the 2010 William L. McGuire Memorial Lecture Award at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium. [American Association for Cancer Research Press Release]

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]

Twitter Follow us on Twitter! @MammaryCell



SCIENCE NEWS

Could Alpha-2 Integrin be a Protein Predictor of Tumor Spread?
Researchers have generated data that lead them to suggest that decreased expression of the protein alpha-2 integrin is predictive of tumor dissemination to distant sites and decreased survival in individuals with either breast or prostate cancer. [Press release from Medical News Today discussing online prepublication in the Journal of Clinical Investigation]

Insulin Levels Found to Affect Breast Cancer Survival
Women treated for breast cancer who have elevated levels of circulating insulin face substantially higher mortality rates than their peers with lower levels, a new study has found. [Press release from the Yale School of Public Health discussing online prepublication in the Journal of Clinical Oncology]

Obese Women with ER-Positive/HER2-Negative Breast Cancer Have Poorer Survival Rates
Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients – those with estrogen receptor (ER)-positive/HER2-negative disease. [Press release from the American Association for Cancer Research discussing data presented at the 33rd Annual Cancer Therapy & Research Center-AACR San Antonio Breast Cancer Symposium]

Estrogen Alone Is Effective for Reducing Breast Cancer Risk
While endogenous estrogen does have a well-known carcinogenic impact, hormone replacement therapy utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk, according to study. [Press release from the American Association for Cancer Research discussing data presented at the 33rd Annual Cancer Therapy & Research Center-AACR San Antonio Breast Cancer Symposium]

Watch Procedure Now  
Use EpiCult-B® to Culture and Characterize
Human Mammary Epithelial Progenitors

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

The Alpha2Beta1 Integrin Is a Metastasis Suppressor in Mouse Models and Human Cancer
Here, researchers have demonstrated that the alpha2beta1 integrin suppresses metastasis in a clinically relevant spontaneous mouse model of breast cancer. [J Clin Invest]

14-3-3(Sigma) Exerts Tumor Suppressor Activity Mediated by Regulation of COP1 Stability
COP1 is a p53-targeting E3 ubiquitin ligase that is downregulated by DNA damage through mechanisms that remain obscure. Here, researchers report that COP1 is not downregulated following DNA damage in 14-3-3(sigma) null cells, implicating 14-3-3(sigma) as a critical regulator in the response of COP1 to DNA damage. [Cancer Res]

Effect of Maternal and Postweaning Folic Acid Supplementation on Mammary Tumor Risk in the Offspring
The findings suggest that a high intrauterine and postweaning dietary exposure to folic acid may increase the risk of mammary tumors in the offspring. Further, they suggest that this tumor-promoting effect may be mediated in part by altered DNA methylation and DNA methyltransferase activity. [Cancer Res]

The Integrin Alpha(v)Beta(3-5) Ligand MFG-E8 is a p63/p73 Target Gene in Triple Negative Breast Cancers but Exhibits Suppressive Functions in ER+ and erbB2+ Breast Cancers
Researchers identified down-regulation of milk fat globule-EGF factor 8 (MFG-E8) as a contributor to breast cancer progression using microarray analysis of laser capture microdissected tissues. [Cancer Res]

Combining Epitope-Distinct Antibodies to HER2: Cooperative Inhibitory Effects On Invasive Growth
Researchers previously reported that combinations of antibodies directed at non-overlapping epitopes of HER2 are endowed with enhanced antitumor effects, probably due to accelerated receptor degradation. Here, researchers extend these observations to three-dimensional mammary cell models, and compare the effects of single monoclonal antibodies with the effects of antibody combinations. [Oncogene]

Transforming Growth Factor-Beta Regulates the Sphere-Initiating Stem Cell-Like Feature in Breast Cancer through miRNA-181 and ATM
In this study, researchers observed that exposure to transforming growth factor-beta increased the population of breast cancer cells that can form mammospheres in suspension, a feature endowed by stem cells. [Oncogene]

Associations of Insulin Resistance and Adiponectin with Mortality in Women with Breast Cancer
Here, researchers evaluate whether low levels of adiponectin and a greater level of insulin resistance are associated with breast cancer mortality and all-cause mortality. [J Clin Oncol]

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Researchers evaluated the effect of trastuzumab or lapatinib in three HER2-overexpressing cell lines. They confirmed the in vitro observations in two neoadjuvant clinical trials in patients with HER2 overexpression. [J Clin Oncol]



INDUSTRY NEWS

Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data
Generex Biotechnology Corporation announced two presentations of data obtained from its on-going phase II trial of its novel immunotherapeutic AE37 vaccine in breast cancer patients. [Generex Biotechnology Corporation Press Release]

Geron Initiates Randomized Phase II Clinical Trial of Imetelstat in Breast Cancer
Geron Corporation announced enrollment of the first patient in a randomized phase II clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer. [Geron Corporation Press Release]

New Clinical Data Evaluating AVEO’s Tivozanib in Combination with Paclitaxel to be Presented at 33rd Annual San Antonio Breast Cancer Symposium
AVEO Pharmaceuticals, Inc. announced that new clinical data from a phase 1b trial evaluating the company’s lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol(R)), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. [AVEO Pharmaceuticals, Inc. Press Release]



POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)



EVENTS (Listed by Date)

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

Cell Culture World Congress 2011 – Optimising Cell Culture Development for Biopharmaceutical, Bioprocessing and Manufacture
February 28-March 2, 2011
Munich, Germany

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

28th Annual Miami Breast Cancer Conference
March 9-12, 2011
Miami, United States

MENA Oncology Conference
March 11-12, 2011
Cairo, Egypt

PITTCON Conference & Expo 2011
March 13-18, 2011
Atlanta, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

Third Annual European Network of Breast Development and Cancer Labs (ENBDC) Workshop: Methods in Mammary Gland Biology and Breast Cancer
April 29 – May 1, 2011
Weggis, Switzerland

World Stem Cells & Regenerative Medicine Congress 2011
May 9-11, 2011
London, United Kingdom

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!



Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us